183 related articles for article (PubMed ID: 31439578)
1. A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.
Glod J; Arnaldez FI; Wiener L; Spencer M; Killian JK; Meltzer P; Dombi E; Derse-Anthony C; Derdak J; Srinivasan R; Linehan WM; Miettinen M; Steinberg SM; Helman L; Widemann BC
Clin Cancer Res; 2019 Nov; 25(21):6302-6308. PubMed ID: 31439578
[TBL] [Abstract][Full Text] [Related]
2. A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma.
Ligon JA; Sundby RT; Wedekind MF; Arnaldez FI; Del Rivero J; Wiener L; Srinivasan R; Spencer M; Carbonell A; Lei H; Shern J; Steinberg SM; Figg WD; Peer CJ; Zimmerman S; Moraly J; Xu X; Fox S; Chan K; Barbato MI; Andresson T; Taylor N; Pacak K; Killian JK; Dombi E; Linehan WM; Miettinen M; Piekarz R; Helman LJ; Meltzer P; Widemann B; Glod J
Clin Cancer Res; 2023 Jan; 29(2):341-348. PubMed ID: 36302175
[TBL] [Abstract][Full Text] [Related]
3. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
[TBL] [Abstract][Full Text] [Related]
4. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations.
Pantaleo MA; Lolli C; Nannini M; Astolfi A; Indio V; Saponara M; Urbini M; La Rovere S; Gill A; Goldstein D; Ceccarelli C; Santini D; Rossi G; Fiorentino M; Di Scioscio V; Fusaroli P; Mandrioli A; Gatto L; Catena F; Basso U; Ercolani G; Pinna AD; Biasco G
Genet Med; 2015 May; 17(5):391-5. PubMed ID: 25188872
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
7. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST.
Pantaleo MA; Astolfi A; Urbini M; Nannini M; Paterini P; Indio V; Saponara M; Formica S; Ceccarelli C; Casadio R; Rossi G; Bertolini F; Santini D; Pirini MG; Fiorentino M; Basso U; Biasco G;
Eur J Hum Genet; 2014 Jan; 22(1):32-9. PubMed ID: 23612575
[TBL] [Abstract][Full Text] [Related]
8. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
10. Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy.
Huss S; Elges S; Trautmann M; Sperveslage J; Hartmann W; Wardelmann E
Expert Rev Anticancer Ther; 2015 Jun; 15(6):623-8. PubMed ID: 25831232
[TBL] [Abstract][Full Text] [Related]
11. Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction.
Nannini M; Astolfi A; Paterini P; Urbini M; Santini D; Catena F; Indio V; Casadio R; Pinna AD; Biasco G; Pantaleo MA
Future Oncol; 2013 Jan; 9(1):121-6. PubMed ID: 23252569
[TBL] [Abstract][Full Text] [Related]
12. SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors.
Italiano A; Chen CL; Sung YS; Singer S; DeMatteo RP; LaQuaglia MP; Besmer P; Socci N; Antonescu CR
BMC Cancer; 2012 Sep; 12():408. PubMed ID: 22974104
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
[TBL] [Abstract][Full Text] [Related]
14. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.
Janeway KA; Kim SY; Lodish M; Nosé V; Rustin P; Gaal J; Dahia PL; Liegl B; Ball ER; Raygada M; Lai AH; Kelly L; Hornick JL; ; O'Sullivan M; de Krijger RR; Dinjens WN; Demetri GD; Antonescu CR; Fletcher JA; Helman L; Stratakis CA
Proc Natl Acad Sci U S A; 2011 Jan; 108(1):314-8. PubMed ID: 21173220
[TBL] [Abstract][Full Text] [Related]
15. [Translational research and diagnosis in GIST].
Wardelmann E
Pathologe; 2012 Nov; 33 Suppl 2():273-7. PubMed ID: 22968735
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
18. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.
von Mehren M; George S; Heinrich MC; Schuetze SM; Yap JT; Yu JQ; Abbott A; Litwin S; Crowley J; Belinsky M; Janeway KA; Hornick JL; Flieder DB; Chugh R; Rink L; Van den Abbeele AD
Clin Cancer Res; 2020 Apr; 26(8):1837-1845. PubMed ID: 31792037
[TBL] [Abstract][Full Text] [Related]
19. Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response.
Yebra M; Bhargava S; Kumar A; Burgoyne AM; Tang CM; Yoon H; Banerjee S; Aguilera J; Cordes T; Sheth V; Noh S; Ustoy R; Li S; Advani SJ; Corless CL; Heinrich MC; Kurzrock R; Lippman SM; Fanta PT; Harismendy O; Metallo C; Sicklick JK
Clin Cancer Res; 2022 Jan; 28(1):187-200. PubMed ID: 34426440
[TBL] [Abstract][Full Text] [Related]
20. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways.
Pantaleo MA; Nannini M; Corless CL; Heinrich MC
Cancer Med; 2015 Jan; 4(1):101-3. PubMed ID: 25165019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
